.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after an average follow-up of 11 months, people with metastatic gastrointestinal cysts that got biomarker-matched therapies based on circulating lump DNA profiling presented a better clinical advantage than those receiving unmatched therapy.